2.27 Swans
Printable View
Would just like to take my hat off to Balance for showing humility and giving credit to how things are playing out now. Has been a long road for many. Few more miles to go but getting there.
Have learnt the hard lesson to not buy or stay in stocks like PEB on the way down when the story changes from positive to negative, but to invest on the way up as the story gets better and better.
This strategy is to let those who are prepared to bear the risk (and pain) to take the loss or the first 100% upside on a speculative stock like PEB but ride the next 1000% by buying off the hardy (or foolish) risk takers when the story turns.
I must say that I am surprised at how quickly the sp has spiked upwards in a matter of less than 2 months with the 3 positive announcements to date.
There have been over 400m shares issued in the last 6 years at between 10c to 61c, and I would have thought that there would be enough profit takers to provide stock at various points on the way up when the story turns.
Has not turned out to be the case with the sp doubling and doubling again with the first two announcements.
Certainly points towards the big shareholders staying in for the long haul - guess they have suffered and endured 6 long years of non-performance so they must assess the upside from here to be much more than just recovering the money they have put in!
Agree..... it's all about the trend. For the last 6 years (or so) PEB has been on a down trend.
The following TA chart shows just quickly PEB changed from this prolonged downtrend via a 'golden cross' in May of this year. This crossing and the large volumes that started trading along with a sharply rising MACD in June/July show an almost classic trend reversal.
Attachment 11813
For those of us who are holding it's now just a matter of sitting tight and riding the rising trend. (Maybe buying more on positive news.)
It's all about DCA and keeping a 'safety margin' between your average holding SP and the current market SP.
GLH.
I think that it is best to stay away from IPOs in general. Always too much hype and expectation from investors particularly for the “back door jobs”. When the dust settles good Opportunities may present themselves. PEB is a good example. I dabbled with it a few years ago and got out at a loss. Purchased again at 26 c after the good news about kaiser. Plexure also shows some promise although the jury is still out. I am also very interested in Bliss,Ike and QEX.
Looks like the sharsies mob have caught the bug, up 11% already.
Just some general thoughts.
If PEB became a buyout target in next 12-24 months, in order to justify a SP of >$1 it would need to generate annual revenue in the vicinity of USD$180M
This would mean an annual turnover of tests in the range of 220,000-250,000. I believe the number of cases of BC would justify this (isn't it 800,000 cases with 80,000 new p.a?). Each case would be tested more than once.
Biotechs will be bought in general for 4-4.5x ann rev if the product is guideline indicated and ins covered. They have one of those two.
Markets are funny things but imo they really need to get guideline support to justify going over $1